LTRN
NASDAQLantern Pharma Inc.
Website
News25/Ratings3
Price$2.31-1.27 (-35.47%)
2026-01-202026-04-23
News · 26 weeks30+200%
2025-10-262026-04-19
Mix1490d
- Other8(57%)
- SEC Filings4(29%)
- Earnings2(14%)
Latest news
25 items- PREmerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added ToxicityLantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Targeting This High-Need Population, Reflecting LP-300's Novel Mechanism of Action and the Rapidly Evolving Post-TKI Standard of Care Among L858R patients in HARMONIC™, those who completed 6 doses or cycles of LP-300 demonstrated a higher median PFS than the overall L858R cohort and those patients that had only 4 doses or cycles of LP-300 Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to seek feedback on proposed protocol amendments to its ongoing P
- PRLantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22Platform Now Available with Introductory, Academic, & Commercial Subscription Tiers Live Debut at Nasdaq MarketSite, New York City — April 16, 2026, 12:00–2:00 PM Eastern Public Demonstrations at AACR 2026, San Diego — Booth 5054, April 17–22 Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world's first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development — is now commercially live and actively onboarding subscribers. Subscriptions are available immediately at
- SECLantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form SCHEDULE 13G filed by Lantern Pharma Inc.SCHEDULE 13G - Lantern Pharma Inc. (0001763950) (Subject)
- PRLantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026Briefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform Monetization Strategy Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced it will host an investor, analyst and shareholder briefing on Thursday, April 9, 2026 at 8:30 AM Eastern featuring a live demonstration of withZeta.ai — the world's first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design. The briefing will be conducted via live webcast and will cover the platform's capabilities and
- SECSEC Form 424B5 filed by Lantern Pharma Inc.424B5 - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form 10-K filed by Lantern Pharma Inc.10-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECLantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesYear of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones LP-300 Phase 2 HARMONIC™ Trial Progress: Continued enrollment and patient follow-up across the United States, Japan, and Taiwan. Completion of targeted enrollment in Japan across five clinical sites including the National Cancer Center Tokyo. Preliminary data presented at the 66th Annual Meeting of the Japan Lung Cancer Society. Type C meeting package submitted to FDA in March 2026, with meeting scheduled for mid-May 2026 seeking feedback on proposed protocol amendments including focusing enrollment on EGFR exon 21 L858R patients and updating th
- PRLantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party ReportLantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website. The third‑party article incorrectly claimed that Panna Sharma has stepped down as President and Chief Executive Officer of Lantern. This claim is false, entirely without basis, and appears designed to mislead investors. No such communication has been issued by the Company or its Board of Directors. Mr. Sharma continues to serve as President, Chief Execu
- PRLantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory CNS Malignancies, Including ATRT, DIPG, GBM, Medulloblastoma, and Ependymoma Lantern Pharma Inc. (NASDAQ:LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for STAR-001 in a planned Phase 1 pediatric clinical trial (IND No. 179145). STAR-001 is a precision oncology compound whose CNS and pediatric CNS indications were initially identified using Lantern's proprietary RADR® AI platfor
- PRLantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ETWebcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2025 operating and financial results webcast on Monday, March 30, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2025 and provide guidan
- PREGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightThe EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua
- PRLantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA. More information about the summit is available at: https://glioblastoma-drugdevelopment.com. Lantern's proprietary AI and machine learning platform, RADR®, powered the development of LP-184 / STAR-001, a novel brain-penetrant therapeutic candidate. This work has driven the creation of Lantern's wholly owned subsidiary, Starlight Therapeutics, which is advancing clinical dev
- SECLantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue SarcomasThird FDA orphan designation for LP-284; Sixth overall for Lantern's A.I.-driven precision oncology pipeline Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. This marks the third orpha
- INSIDERSEC Form 4 filed by Director Silberstein David S.4 - Lantern Pharma Inc. (0001763950) (Issuer)
- INSIDERSEC Form 4 filed by Director Chandru Vijay4 - Lantern Pharma Inc. (0001763950) (Issuer)
- INSIDERSEC Form 4 filed by Director Schalop Lee Troy4 - Lantern Pharma Inc. (0001763950) (Issuer)
- INSIDERSEC Form 4 filed by Director Keyser D Jeffrey4 - Lantern Pharma Inc. (0001763950) (Issuer)
- INSIDERSEC Form 4 filed by Director Maccecchini Maria-Luisa4 - Lantern Pharma Inc. (0001763950) (Issuer)
- PRLantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma CompaniesThe A.I. Center of Excellence is planned to be based in Bengaluru and focus on large scale data-engineering, development and refinement of state-of-the-art ML-ready disease models and integration with global biopharma customers and partners. This strategic initiative positions Lantern to scale its proven AI capabilities and platform across oncology and into new disease categories, meeting growing biopharma partner demand. Hiring for initial positions has already been initiated and Lantern anticipates that expansion and hiring will be cash flow neutral to the Company. Lantern Pharma Inc. (NASDAQ:LTRN), a pioneer in AI-driven precision oncology and computational therapeutic developm
- INSIDERSEC Form 4 filed by Chief Scientific Officer Bhatia Kishor G.4 - Lantern Pharma Inc. (0001763950) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Margrave David R.4 - Lantern Pharma Inc. (0001763950) (Issuer)
- PRLantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 TrialsBiomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all primary endpoints. LP-184 demonstrated clinical benefit in multiple highly aggressive cancers with a 54% disease control rate at or above therapeutic dose levels. Multiple Phase 1b/2 clinical trials are now being planned across cancer indications and supported by 3 FDA Orphan Drug, 2 FDA Fast Track Designations and a Rare Pediatric Disease Designation. Detailed webinar with management and KOL from Fox Chase Cancer Center highlighting the drug-candidate and patient insights can be found at "Ins